Bio-Rad Laboratories (BIO) Net Income towards Common Stockholders (2009 - 2026)

Bio-Rad Laboratories (BIO) has reported Net Income towards Common Stockholders for 18 consecutive years, with $371.4 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Net Income towards Common Stockholders rose 16.87% year-over-year to $371.4 million in Q2 2026; TTM through Jun 2026 was $222.4 million, a 30.33% decrease from a year earlier, with the FY2025 full-year figure at $759.9 million, up 141.2% from the prior year.
• Net Income towards Common Stockholders was $371.4 million for Q2 2026 at Bio-Rad Laboratories, up from -$527.1 million in the prior quarter.
• Over five years, Net Income towards Common Stockholders peaked at $827.8 million in Q4 2022 and troughed at -$3.4 billion in Q1 2022.
• A 5-year average of -$305.8 million and a median of $66.5 million in 2023 frame the typical range for Net Income towards Common Stockholders.
• Across the five-year window, Net Income towards Common Stockholders soared 514.74% in 2024 and plunged 923.59% in 2026, its largest moves.
• Over 5 years, Net Income towards Common Stockholders stood at $827.8 million in 2022, then tumbled by 57.75% to $349.7 million in 2023, then tumbled by 304.67% to -$715.8 million in 2024, then soared by 200.59% to $720.0 million in 2025, then slumped by 48.42% to $371.4 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at $371.4 million (Q2 2026), -$527.1 million (Q1 2026), and $720.0 million (Q4 2025), per Business Quant data.